Furthermore, none of the currently tested biomarkers reliably addressed the antiangiogenic effects of rapalogues and, for instance, little is known of the effects of rapalogues on VEGF and sVEGFR2 in plasma of patients treated for renal cell carcinomas. The gene discussed is VEGFA; the disease is renal cell carcinoma.